NYSE:WAT - Waters Stock Price, Price Target & More

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters announced that its Board of Directors has authorized a share repurchase plan on Tuesday, April 24th 2018, which permits the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 18.2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its stock is undervalued.

Waters Co. (NYSE:WAT) announced its quarterly earnings results on Tuesday, April, 24th. The medical instruments supplier reported $1.59 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.55 by $0.04. The medical instruments supplier earned $530.70 million during the quarter, compared to analyst estimates of $534.17 million. Waters had a net margin of 1.14% and a return on equity of 25.80%. The company's revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.46 earnings per share. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Waters.

Waters issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $8.10-8.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.19.

16 analysts have issued 1-year price targets for Waters' shares. Their forecasts range from $180.00 to $230.00. On average, they anticipate Waters' stock price to reach $204.7857 in the next year. This suggests a possible upside of 4.5% from the stock's current price. View Analyst Ratings for Waters.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM) and Harvard Bioscience (HBIO).

Media coverage about WAT stock has been trending somewhat negative this week, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Waters earned a media sentiment score of -0.02 on Accern's scale. They also gave headlines about the medical instruments supplier an impact score of 45.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Waters' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (3.26%), Fenimore Asset Management Inc. (0.37%), Assenagon Asset Management S.A. (0.12%), Bank of Montreal Can (0.11%), Copper Rock Capital Partners LLC (0.08%) and Retirement Systems of Alabama (0.05%). Company insiders that own Waters stock include Arthur G Caputo, Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Baillie Gifford & Co., State of Alaska Department of Revenue, Fenimore Asset Management Inc., Retirement Systems of Alabama, Copper Rock Capital Partners LLC, Gateway Investment Advisers LLC and Raymond James Trust N.A.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meag Munich Ergo Kapitalanlagegesellschaft MBH, DnB Asset Management AS, Bank of Montreal Can, Denali Advisors LLC, Fjarde AP Fonden Fourth Swedish National Pension Fund, IFM Investors Pty Ltd and Pennsylvania Trust Co. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $196.01.

Waters has a market capitalization of $15.52 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]